GDNF fusion protein for targeted‐drug delivery across the human blood–brain barrier
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Glial‐derived neurotrophic factor (GDNF) is a neurotrophin that could be developed as a neurotherapeutic for Parkinson's disease, stroke, and motor neuron disease. However, GDNF does not cross the blood–brain barrier (BBB). Human GDNF was re‐engineered by fusion of the mature GDNF protein to the carboxyl terminus of the chimeric monoclonal antibody (MAb) to the human insulin receptor (HIR). The HIRMAb‐GDNF fusion protein is bi‐functional, and both binds the HIR, to trigger receptor‐mediated transport across the BBB, and binds the GDNF receptor (GFR)‐α1, to activate GDNF neuroprotection pathways behind the BBB. COS cells were dual transfected with the heavy chain (HC) and light chain fusion protein expression plasmids, and the HC of the fusion protein was immunoreactive with antibodies to both human IgG and GDNF. The HIRMAb‐GDNF fusion protein bound with high affinity to the extracellular domain of both the HIR, ED 50 = 0.87 ± 0.13 nM, and the GFRα1, ED 50 = 1.68 ± 0.17 nM. The HIRMAb‐GDNF fusion protein activated luciferase gene expression in human neural SK‐N‐MC cells dual transfected with the c‐ret kinase and a luciferase reporter gene under the influence of the rat tyrosine hydroxylase promoter, and the ED 50, 1.68 ± 0.45 nM, was identical to the ED 50 in the GFRα1 binding assay. The fusion protein was active in vivo in a rat middle cerebral artery occlusion model, where the stroke volume was reduced 77% (P < 0.001). In conclusion, these studies describe the re‐engineering of GDNF, to make this neurotrophin transportable across the human BBB. Biotechnol. Bioeng. 2008;100: 387–396. © 2007 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kobayashi, T., Ahlenius, H., Thored, P., Kobayashi, R., Kokaia, Z., & Lindvall, O. (2006) · Stroke · doi:10.1161/01.str.0000236025.44089.e1 · Cited by 201 · cited 2×
“Recent work shows that chronic treatment of the brain with intra-cerebral GDNF may promote striatal neurogenesis following stroke (Kobayashi et al., 2006).”
Zhang, Y., & Pardridge, W. M. (2001) · Stroke · doi:10.1161/01.str.32.6.1378 · Cited by 175 · cited 4×
“The permanent MCAO model was performed as described previously in adult Sprague-Dawley rats (Zhang and Pardridge, 2001a).”
InfluentialSelf-citation
Cited by
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 528
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
Self-citationA Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Self-citation
Metadata
- Authors
- Boado, R. J., Zhang, Y., Zhang, Y., Wang, Y., & Pardridge, W. M.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2007-12-13
- Volume
- 100
- Issue
- 2
- Pages
- 387-396
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2083284350
- Cited by
- 96
- References
- 2
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.